Results 21 to 30 of about 313,244 (194)

Abrin immunotoxin: targeted cytotoxicity and intracellular trafficking pathway.

open access: yesPLoS ONE, 2013
BackgroundImmunotherapy is fast emerging as one of the leading modes of treatment of cancer, in combination with chemotherapy and radiation. Use of immunotoxins, proteins bearing a cell-surface receptor-specific antibody conjugated to a toxin, enhances ...
Sudarshan Gadadhar, Anjali A Karande
doaj   +2 more sources

Production and Verification of Anti-Tumor Activity of Monoclonal Anti-EGFR-Recombinant PE38 Immunotoxin in A431 Tumor Cells [PDF]

open access: yesImmunoAnalysis, 2021
Background: Tumor growth and progression depend largely on the activity of cell membrane receptors like epidermal growth factor receptor (EGFR). This receptor plays a significant role in the growth and survival of many solid tumors.
Khalil Hajiasgharzadeh   +2 more
doaj   +1 more source

A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy. [PDF]

open access: yesInt J Mol Sci, 2021
Prostate cancer (PCa) is the second most common cancer in men, causing more than 300,000 deaths every year worldwide. Due to their superior cell-killing ability and the relative simplicity of their preparation, immunotoxin molecules have great potential ...
Xing Y   +7 more
europepmc   +2 more sources

Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors [PDF]

open access: yesActa Naturae, 2015
Irina V. Balalaeva   +2 more
exaly   +2 more sources

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. [PDF]

open access: yesClin Cancer Res, 2011
Recombinant immunotoxins are fusion proteins that contain the cytotoxic portion of a protein toxin fused to the Fv portion of an antibody. The Fv binds to an antigen on a target cell and brings the toxin into the cell interior, where it arrests protein ...
Kreitman RJ, Pastan I.
europepmc   +2 more sources

Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. [PDF]

open access: yesClin Colorectal Cancer, 2019
Mesothelin (MSLN) is a cell surface glycoprotein expressed at a high level on many malignancies, including pancreatic adenocarcinoma, serous ovarian cancer, and epithelioid mesothelioma. MSLN-targeted recombinant immunotoxins (RITs) consist of an anti-MSLN Fv fused to the catalytic domain of Pseudomonas exotoxin A.
Cerise A   +4 more
europepmc   +4 more sources

Immunogenicity of therapeutic recombinant immunotoxins [PDF]

open access: yesImmunological Reviews, 2016
SummaryRecombinant immunotoxins (RITs) are chimeric proteins designed to treat cancer. They are made up of an Fv or Fab that targets an antigen on a cancer cell fused to a 38‐kDa portion of Pseudomonas exotoxin A (PE38). Because PE38 is a bacterial protein, it is highly immunogenic in patients with solid tumors that have normal immune systems, but much
Ronit, Mazor   +2 more
openaire   +2 more sources

Crotamine-based recombinant immunotoxin targeting HER2 for enhanced cancer cell specificity and cytotoxicity

open access: yes, 2023
Crotamine, one of the major toxins present in the venom of the South American rattlesnake Crotalus durissus terrificus, exhibits potent cytotoxic properties and has been suggested for cancer therapy applications. However, its selectivity for cancer cells
Minh Quan Nguyen   +8 more
core   +1 more source

Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins [PDF]

open access: yesThe American Journal of Pathology, 2018
Recombinant immunotoxins (RITs) are genetically engineered proteins being developed to treat cancer. They are composed of an Fv that targets a cancer antigen and a fragment of a bacterial toxin that kills tumor cells. Because the toxin is a foreign protein, it is immunogenic.
Ronit, Mazor, Emily M, King, Ira, Pastan
openaire   +2 more sources

Home - About - Disclaimer - Privacy